Capricor announces that individuals with Duchenne treated with deramiocel had significantly less progression in loss of upper limb function

Capricor Therapeutics received early funding from CureDuchenne, and today Capricor released new data reporting that individuals treated with deramiocel over three years experienced an average decline in Performance of the Upper Limb (PUL 2.0) total score of 3.46 points, compared to a 7.19-point decline in the external comparator group (p=0.019). Capricor reports that this equates to a 52% slowing of disease progression.  Capricor’s Biologics License Application (BLA) for approval for the treatment of the cardiomyopathy associated with Duchenne has been accepted by the FDA, with a with a target action date set for August 31, 2025.

Read the full new release:
https://www.capricor.com/investors/news-events/press-releases/detail/308/capricor-therapeutics-announces-positive-data-demonstrating